• Arsanis, a Waltham, Mass. - based clinical stage biopharmaceutical company focused on monoclonal antibodies, filed for an $ 58 million IPO. (fortune.com)
In addition, the company collaborates with biopharmaceutical companies in the development of companion diagnostic tests and technologies for various cancer therapies, helping to realize the promise of precision oncology. (nanostring.gcs-web.com)
• NightstaRx, a London - based biopharmaceutical company developing therapies for retinal dystrophies, raised $ 45 million in a Series C funding. (fortune.com)